Introduction
Infantile spasms are refractory to the usual antiepileptic drugs, as assessed in more than 50 trials. Hormonal therapy has been used since 1958. Vigabatrin (a gaminobutyric acid (GABA) transaminase inhibitor) has rapidly gained popularity in Europe. Comparison of the efficacy, relapse rate, short-term and long-term effects, presence or absence of other seizures and side effects of hormonal therapy and vigabatrin has been insufficient. A large data-based critical literature review by the American Academy of Neurology (AAN) and the Child Neurology Society (CNS) 2004 [1 ], reviews by the author [2,3,4 , 5 ,6] , and a recent prospective randomized study from the UK comparing the effectiveness of hormonal therapy and vigabatrin [7] are presented is this review. In addition, some new data on the etiology of infantile spasms are presented.
Therapy: short-term outcome
The following sections present the choices of anticonvulsant.
What is the most effective treatment: corticotrophin or oral steroids?
Recommendations of the AAN and CNS review were based on a four-tiered scheme [1 ] . The studies reviewed were placed in four categories as follows. Class I -prospective, randomized, controlled trial; Class IIprospective, controlled trial, lacking one of the criteria (a)-(d); Class III -controlled trial in a representative population; Class IV -evidence from uncontrolled studies. Criteria (a)-(d) -(a) primary outcome is clearly defined; (b) exclusion criteria are clearly defined; (c) drop-outs adequately counted and cross-over used; (d) baseline characteristics equivalent among treatment groups.
One Class I, one Class II and five prospective Class III studies demonstrated that 'ACTH is probably effective in the short-term treatment of infantile spasms and in the resolution of hypsarrhythmia' [1 , p. 1673]. One Class II and several Class III studies showed the limited efficacy of oral corticosteroid treatment in infantile spasms. It was concluded that adrenocorticotropic hormone or corticotropin (ACTH) is more effective than corticosteroids, which lacked any evidence of effectiveness in the treatment of infantile spasms. Use of ACTH is recommended.
However, a large randomized UK study [7 ] of 107 children using much larger doses (prednisolone 40 mg/ day versus 2 mg/kg prednisone in the earlier studies) did not show any difference in comparison to tetracosactide (Synachten Depot) 0.5 mg/day (40 IU) given on alternate days. Response rates on day 14 were 70% and 76%, respectively. This study excluded infants with tuberous sclerosis in which vigabatrin has been considered to be the drug of choice.
ACTH is recommended by the author because adrenal hypofunction is to be expected after very large doses of prednisolone.
The mechanism of action of ACTH on infantile spasms is unknown. According to one recent theory, ACTH administration downregulates the expression of corticotrophinreleasing hormone and stress hormones [8, 9] , and the action of ACTH via steroids may be of minor importance.
Because oral steroids also seem to be as effective as ACTH when used in maximal doses [7] , other mechanisms may also be involved [10 ] . Hormonal therapy may accelerate physiological events during critical stages of brain development through action as a trophic hormone [2, 5 ]. ,11]; and another prospective study, including 30 children, in which the therapy was individualized according to etiology, with a starting dose of 3 IU/kg given for a short period [5 ,12] .
Dosage of corticotrophin
Small doses and short duration of therapy have been recommended [2, 3, 6] .
Vigabatrin
In the AAN and CNS review [1 ], 14 studies met the inclusion criteria for analysis of vigabatrin treatment: one randomized, placebo-controlled study (Class I), two Class III studies and five retrospective case series (Class IV). The dosages of vigabatrin varied from 18 to 200 mg/kg/ day. The small Class I study showed that difference in response was not statistically significant when compared with placebo. Two Class III randomized controlled trials and the majority of Class IV trials showed that less than half of those treated responded. It was concluded that 'vigabatrin is possibly effective for the short-term treatment of infantile spasms'. 'Vigabatrin is considered by the Food and Drug Administration to be experimental and unproven for all indications, and is not licensed for use in the United States' (p. 1676).
In a recent randomized UK study (excluding tuberous sclerosis patients) [7 ] , vigabatrin was effective in 54% of the children. The difference in favour of hormonal treatment on spasms (70%) was significant at day 14. Hypsarrhythmia resolved significantly more often with hormonal treatment [7 ] .
Vigabatrin seems to be less effective than hormonal treatment in the short-term treatment of infantile spasms.
Tuberous sclerosis
There is evidence to suggest that vigabatrin is the treatment of choice in patients with tuberous sclerosis with infantile spasms, with a mean response rate of 74% in eight studies [3, 4 ] . However, the response rates with ACTH (73%) and vigabatrin are comparable [4 ] .
Because treatment with ACTH is always given for a specified period and vigabatrin is administered for an indefinite period, vigabatrin is a better choice.
Relapses
The relapse rates after corticotrophin treatment were 15-24% in the Class I-III studies, 33% in the Class II study, and 19-24% in Class III studies [1 ] . There are insufficient data on the relapse rate after vigabatrin administration. However, the numbers of patients who were seizure-free at 3-4 months after ACTH or vigabatrin treatment are very similar (42-44%) [4 ] .
It seems highly likely that the gross EEG abnormality of hypsarrhythmia is responsible, at least in part, for the cognitive decline, irrespective of other seizure types. The outlook is much improved for children who respond to treatment.
Therapy: long-term outcome
Seven Class III and IV studies have provided results on the long-term outcome of hormonal treatment [1 ]. None was randomized or controlled, five were prospective and two were retrospective series. The total number of patients was 457 and the mean number of patients per study was 65. The mean duration of follow-up was 50 months to 10 years. The data have produced conflicting results. The conclusion reached in the review by the AAN and CNS was that 'there is insufficient data to conclude that any treatment improves the long-term prognosis for cognitive outcome or reduce the later incidence of epilepsy, or show that early initiation of treatment should be used to improve the long-term outcome' (p. 1679). The long-term outcome after vigabatrin has not been sufficiently evaluated.
This review does not include a large Finnish cohort including 214 children with follow-up to adulthood [6] . In this study the death rate, autopsy findings, intellectual outcome (using standardized psychometric assessments), education, occupations, psychiatric disorders and occurrence of epilepsy and follow-up of EEG were reported. My own conclusion regarding long-term results is based on the findings of this study. They show that patients with infantile spasms who had responded with corticotrophin have a better cognitive outcome than other treatment groups. This holds true both for patients with a cryptogenic etiology (14/20 patients or 70%) and known etiology (18/78 or 23%) [4 ] . The long-term cognitive outcome was better in children treated with smaller doses (20-40 IU/day) than with larger doses (120 IU/day) [3] . Early treatment (<6 weeks) resulted in a better cognitive outcome, as was also found in three other series that have been reviewed [6] .
A recent retrospective study by Kivity et al. [13 ] of patients treated with high-dose tetracosactide followed by oral steroids (for about 9 months) has resulted in a normal cognitive outcome in all patients when treated within 1 month of onset of infantile spasms, but only in 40% when treated later. This study included only cryptogenic patients. The number of patients with a normal outcome in the whole series (18%) did not differ from another study in which shorter treatments were used (17%) [6] .
Although evaluation of treatment in terms of cognitive outcome is difficult because double-blind, placebocontrolled trials would be unethical, there does seem to be strong evidence for the importance of adequate early intervention [6, 14] .
Side effects
The side effects of ACTH include infections, arterial hypertension, hypertrophic cardiomyopathy and adrenal hypofunction. For infants with a history of frequent respiratory infections, prophylactic trimetoprim-sulfaxazole therapy is recommended. Hypertension should be monitored and treated. In hypertensive patients, the heart should be monitored using ultrasound. The dose should be tapered slowly. Full cortisol substitution should be given after ACTH and increased during periods of stress such as high fever [2] .
Unlike the side effects of vigabatrin, the side effects of steroids are well known and treatable. They are also reversible upon discontinuation of the drug. To minimize the side effects, the child should be closely watched and therapy should be given using the minimal effective dosage for the minimal effective time possible.
A new concern has arisen in relation to the use of vigabatrin -concentric visual field defects (VFDs), which seem to be permanent and cause a considerable handicap. VFDs are, for example, sufficient to prevent individuals from driving. Concerns also exist especially in children who might have poor underlying visual function as part of their overall neurological disabilities. VFDs may appear after only 6-8 weeks of treatment [15, 16] . VFDs have been found in a total of 35% of older children in six published series, and in 39% of adults in 15 series [4 ] . New markers of early damage are being developed (e.g. the scotopic threshold response, an electroretinographic marker) [17] .
It is likely that VFDs are as common in children as in adults, and there is no minimum period of safe use. When children with infantile spasms are capable of undergoing a complete ophthalmologic examination to document whether there are indeed visual problems associated with the use of vigabatrin, an examination should be performed. Since no methods are currently available to identify VFDs, steroids should be used as treatment of first choice.
Recent reports of studies in animals have also been alarming. Activation of GABAa receptors may trigger apoptotic neurodegeneration [18] . Drugs that increase brain concentrations of GABA, like vigabatrin, can also cause apoptotic degeneration in the developing brain [19 ] . The vulnerability period coincides with the brain spurt period. Damage can be seen early and at low doses of vigabatrin. Of greatest concern is the axonal degeneration which is irreversible [20] .
The possible benefits of vigabatrin therapy do not justify the risks because of irreversible effects on the retina and possibly also on neurons in the developing brain.
In general, the above-mentioned reviews show the difficulties in comparing the results of clinical series of infantile spasms from the literature, because of their nonhomogeneity and different definitions of response rates used in the series. A good response rate should include both total cessation of the spasms and also disappearance of hypsarrhythmia in the sleep EEG. Follow up varies from several months to several years. Some authors have treated only children whose outcome was likely to be favourable with a number of drop-outs from the series. Furthermore, the modalities of treatment have been extremely variable. Side effects of therapy (for example, hypertension during steroid therapy) are often poorly described.
The outcome is also strongly influenced by the etiology. Structural abnormalities often imply a bad prognosis while cryptogenic cases (with no known pathology) have the best outcome.
New etiological aspects
The following sections detail the causes of infantile spasms
Genetics
The Aristales-related homeobax gene (ARX) has emerged as an important gene with crucial roles in brain development and human disorders. X-linked recessive infantile spasms have recently been associated with mutations in the ARX gene [21] . A mutation in the ARX gene has also been reported in sporadic cryptogenic infantile spasms [22] . Mutations of ARX are associated with striking pleiotrophy and consistent genotype-phenotype correlations [23 ] . It is now clear that different mutations in the ARX gene produce various clinical symptoms. A nearly continuous series of developmental disorders begins with hydrancephaly, lissencephaly, and agenesis of the corpus callosum, and ends with a series of overlapping syndromes with apparent normal structure [24] .
Metabolic diseases
The study of Sadlier et al. [25] demonstrates that infantile spasms may be an important clinical manifestation of mitochondrial disorders in children, and that in spite of this blood lactate may be normal. Children with unexplained infantile spasms, particularly with mental delay, should be investigated; at least four tests of blood lactate in both the fasted and postprandial state are necessary.
Tuberous sclerosis
Neuropsychiatric problems are often found in tuberous sclerosis patients [26] . One of these problems is autism, which is not associated with any special genotype [27] . Tubers in the temporal region have been associated with autistic symptoms [4 ,5 ,14,26] . The presence of a TSC2 mutation was found to carry a higher risk of low IQ, autistic disorder and infantile spasms than a TSC1 mutation [27] . The study of O'Callaghan et al. [28] showed that both the number of tubers and a history of infantile spasms are independently associated with cognitive deficiency.
Defective cortical development
A rare regional malformation, posterior quadrantic dysplasia of the brain in children suffering from infantile spasms, was reported by D'Agostino et al. [29] . Widespread cortical dysplasia is more frequent in the posterior quadrant and represents either hemi-hemimegalencephaly or multilobar cortical dysplasia. Intractable epilepsy in these patients may be alleviated by a large quadrantic temporoparieto-occipital resection.
Conclusion
There is still a lack of consensus about the drug of first choice in infantile spasms. The common use of vigabatrin as the first-line drug in Europe is only based on its ease of use, not on effectiveness. The recommendations of the present author are as follows:
(1) Use ACTH as the first choice for treatment because it is a safe drug when used at the minimal effective dose and duration; vigabatrin is the first-line drug for the treatment of tuberous sclerosis. There are several important goals for the future. Identification of the frequency of VFDs and quantification of the long-term effects in general (epilepsy, cognitive and behavioural outcome) after vigabatrin administration in children treated for their spasms. In addition, predictive methods for vigabatrin retinal toxicity need to be found. Finally, understanding of brain maturation should be the main focus of studies to elucidate the pathophysiological mechanisms of infantile spasms which remain unclear.
More accurate etiological diagnoses can be made. Various genetic patterns, mitochondrial diseases, and new malformation syndromes have been recognized.
The prognosis in tuberous sclerosis can be better predicted. The number of tubers and infantile spasms are important in the prediction of outcome. Location of tubers may be important for the cognitive, behavioural and epileptic outcome of the child with tuberous sclerosis.
